Mitom ycin Syn th etic Stu d ies: Ster eocon tr olled a n d Con ver gen t
Syn th esis of a F u lly Ela bor a ted Azir id in om itosa n e
Robert S. Coleman,* Franc¸ois-Xavier Felpin, and Wei Chen
Department of Chemistry, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210
coleman@chemistry.ohio-state.edu
Received J une 25, 2004
Full details of a stereocontrolled and convergent synthetic route to 9a-desmethoxymitomycin A (1)
are reported. The target molecule possesses the parent tetrahydropyrrolo[1,2-a]indole ring system
characteristic of the mitomycin family of antitumor agents. The synthesis was based on the
diastereocontrolled addition of a fully elaborated cinnamylstannane to a pyrrolidine-based
N-acyliminium ion as the key convergent step, which resulted in the installation of the C9 and
C9a stereogenic centers.
In tr od u ction
Numerous efforts at the total synthesis of mitomycins
and related compounds have been reported, and novel
synthetic approaches are still being reported after nearly
half a century of extensive research.8 Starting with the
first total synthesis of mitomycins A and C reported in
1977 from the Kishi group,9 there have been several
subsequent successful total syntheses10 and an innumer-
able variety of synthetic approaches to the mitomycins
and the structurally11 and functionally12 related natural
products FR900482 and FR66979. The sustained and
vigorous interest in this family of natural products is
testament to their relevance as synthetic targets. The
densely and diversely functionalized ring system of these
natural products presents an attractive and challenging
objective for the practitioner of targeted organic synthe-
sis. In this article, we report the full details of a novel
synthetic route to the highly elaborated aziridinomito-
sane 113 that provides a strategically unique, syntheti-
cally efficient, and convergent entry to the tricyclic
tetrahydropyrrolo[1,2-a]indole ring system of the mito-
mycins.
Mitomycins A and B were isolated from Streptomyces
caespitosus by Hata and co-workers and were found to
possess potent antitumor and antibiotic activity.1 The
isolation of mitomycin C from the same fermentation
broth was reported subsequently. These antitumor agents
have been studied in detail with respect to mechanism
of action and clinical utility,2 and the synthetic literature
describing approaches to the total synthesis of the
mitomycins is extensive and well-appreciated.3
Mitomycin C is used clinically as a cancer chemothera-
peutic agent against a variety of solid tumors. This agent
forms covalent cross-links with duplex DNA4 by alkylat-
ing deoxyguanosine at the C2-amino group within the
DNA minor groove in 5′-d(CG)-3′ sequences.5,6 These
agents require bioreduction from the quinone to hydro-
quinone oxidation state to generate the active form of the
drug.7
The central premise of our synthetic approach to the
ring system of the mitomycins (2) was based on a
(1) Hata, T.; Hoshi, T.; Kanamori, K.; Matsumae, A.; Sano, Y.;
Shima, T.; Sugawara, R. J . Antibiot. Ser. A 1956, 9, 141.
(2) (a) Bradner, W. T. Cancer Treat. Rev. 2001, 27, 35. (b) Tomasz,
M.; Palom, Y. Pharmacol. Ther. 1997, 76, 73.
(3) Remers, W. A. Mitomycins and porfiromycin. In The Chemistry
of Antitumor Antibiotics; Wiley-Interscience: New York, 1979; pp 221-
276.
(4) Iyer, V. N.; Szybalski, W. Proc. Natl. Acad. Sci. U.S.A. 1963,
50, 355.
(5) (a) Tomasz, M.; Lipman, R.; Chowdary, D.; Pawlak, J .; Verdine,
G. L.; Nakanishi, K. Science 1987, 235, 1204. (b) Tomasz, M.; Lipman,
R.; McGuinness, B. F.; Nakanashi, K. J . Am. Chem. Soc. 1988, 110,
5892.
(8) (a) Coleman, R. S. Curr. Opin. Drug Discovery Dev. 2001, 4, 435.
(b) Danishefsky, S. J .; Schkeryantz, J . M. Synlett 1995, 475. (c)
Fukuyama, T.; Yang, L. Total Synthesis of Mitomycins. In Studies in
Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier: New
York, 1993; pp 433-471.
(9) (a) Fukuyama, T.; Nakatsubo, F.; Cocuzza, A. J .; Kishi, Y.
Tetrahedron Lett. 1977, 4295. (b) For a review of work from the Kishi
group, see: Kishi, Y. J . Nat. Prod. 1979, 42, 9388.
(10) (a) Fukuyama, T.; Yang, L. J . Am. Chem. Soc. 1987, 109, 7881.
(b) Fukuyama, T.; Yang, L. J . Am. Chem. Soc. 1989, 111, 8303.
(11) (a) Uchida, I.; Takase, S.; Kayakiri, H.; Kiyoto, S.; Hashimoto,
M.; Tada, T.; Koda, S.; Morimoto, Y. J . Am. Chem. Soc. 1987, 109,
4108. (b) Shimomura, K.; Hirai, O.; Mizota, T.; Matsumoto, S.; Mori,
J .; Shibayama, F.; Kikuchi, H. J . Antibiot. 1987, 40, 600.
(6) Mallard, J . T.; Weidner, M. F.; Raucher, S.; Hopkins, P. B. J .
Am. Chem. Soc. 1990, 112, 3637.
(7) Iyer, V. N.; Szybalski, W. Science 1964, 145, 55.
10.1021/jo048924i CCC: $27.50 © 2004 American Chemical Society
Published on Web 09/23/2004
J . Org. Chem. 2004, 69, 7309-7316
7309